Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
24,683,081

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $44.40, marking a +1.09% move from the previous day.

Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates

Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.

Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study

Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.

Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx

Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.

Pfizer (PFE) Stock Moves -1.78%: What You Should Know

Pfizer (PFE) closed the most recent trading day at $45.17, moving -1.78% from the previous trading session.

AbbVie Settles With Pfizer for Humira Biosimilar in U.S.

AbbVie (ABBV) strikes a deal with Pfizer to launch its biosimilar of Humira in the United States in November

Swarup Gupta headshot

Dow 30 Stock Roundup: BA's $383M Modification Contract, MSFT's Army Contract

The Dow recovered from two weeks of losses to post strong gains this week.

Pfizer (PFE) Up 4.3% Since Last Earnings Report: Can It Continue?

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Roche (RHHBY) to Acquire Jecure and Enter the NASH Space

Roche (RHHBY) is all set to acquire biotech Jecure Therapeutics, which focuses on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis.

Kinjel Shah headshot

4 Big Pharma Stocks to Add to Your Portfolio in December

The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.

Pfizer (PFE) Gains But Lags Market: What You Should Know

Pfizer (PFE) closed at $44.90 in the latest trading session, marking a +1.88% move from the prior day.

Galapagos' Osteoarthritis Candidate Gets Fast Track Status

Galapagos' (GLPG) GLPG1972/S201086 gets Fast Track designation by the FDA for the treatment of osteoarthritis.

Pfizer's Epilepsy Drug Lyrica Gets Pediatric Exclusivity

Pfizer (PFE) receives pediatric exclusivity for its epilepsy drug, Lyrica, extending the exclusivity period to Jun 30, 2019.

Aileron Inks Collaboration Deal With Pfizer for Cancer Combo

Aileron Therapeutics (ALRN) signs a clinical trial collaboration contract with Pfizer to study the combo of Aileron's ALRN-6924 and Pfizer's Ibrance for treating MDM2-amplified cancers. Stock rises.

Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan

GlaxoSmithKline (GSK) along with partner J&J gains approval for two-drug HIV regimen Juluca from the Japanese Ministry of Health, Labour and Welfare to benefit patients in the country.

The Zacks Analyst Blog Highlights: Boeing, Microsoft, Johnson & Johnson, Chevron and Pfizer

The Zacks Analyst Blog Highlights: Boeing, Microsoft, Johnson & Johnson, Chevron and Pfizer

Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss

Spark Therapeutics (ONCE) announces approval in Europe for its gene therapy, Luxturna, for treating inherited retinal dystrophy with RPE65 mutation. Novartis will develop and distribute it in Europe.

The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca

The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca

Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs

FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs

Swarup Gupta headshot

Dow 30 Stock Roundup: Boeing to Supply 40 737 MAX 8 to Jeju Air, Pfizer Gets FDA Nod

The Dow traversed a particularly difficult holiday-shortened week.

Pfizer's FDA Nod for Cancer Drug is Four in a Row in 90 Days

Pfizer (PFE) wins an FDA nod for Daurismo in combination with low-dose cytarabine regarding newly-diagnosed AML in adults. This is the fourth cancer drug approval on the trot in less than 90 days.

FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz

The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.

Corcept Initiates Phase III Study for Cushing's Syndrome

Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.

Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails

Pfizer's (PFE) late-stage advanced ovarian study on Bavencio (avelumab) fails to meet the primary endpoints.

Pfizer (PFE) Gains As Market Dips: What You Should Know

Pfizer (PFE) closed the most recent trading day at $44.20, moving +1.57% from the previous trading session.